A2 vs Regular Milk for Lactose Intolerance
Trial Summary
What is the purpose of this trial?
Cow's milk contains two types of β-casein: A1 and A2. It is evident from human clinical trials that milk with A1 protein produces more hydrogen and symptoms of lactose intolerance. A pro-inflammatory μ-opioid peptide BCM-7 is released from A1 but not from A2. Milk containing A1 β-casein produced more inflammatory markers than A2 β-casein. This is a double-blinded, randomized, controlled trial conducted to determine if there are changes in inflammatory markers following two weeks of milk feeding, due to milk containing A1 and A2 beta-casein as compared to milk containing only A2 beta-casein.
Will I have to stop taking my current medications?
The trial requires participants to stop using treatments and products for dairy intolerance, like Lactaid® Dietary Supplements, during the study. If you are using any other medications, the protocol does not specify, so it's best to discuss with the study staff.
What data supports the effectiveness of A2 milk as a treatment for lactose intolerance?
Is A2 milk safe for people with lactose intolerance?
How does A2 milk differ from other treatments for lactose intolerance?
A2 milk is unique because it contains only A2 beta-casein protein, unlike regular milk which contains both A1 and A2 proteins. This difference may make A2 milk easier to digest for some people with lactose intolerance, as A1 protein is thought to cause digestive discomfort in some individuals.7891011
Research Team
Dennis Savaiano, PhD
Principal Investigator
Purdue University
Eligibility Criteria
Adults aged 18-65 with a history of lactose intolerance who have avoided dairy for at least a month can join. They must be willing to attend all study visits, avoid other dairy intolerance treatments during the trial, and not have conditions like severe ulcers, diabetes, milk allergies, heart failure or recent drug/alcohol abuse.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention Phase 1
Participants consume the first randomized milk for 14 days and undergo hydrogen breath test on day 15
Intervention Phase 2
Participants consume the second randomized milk for 14 days and undergo hydrogen breath test on day 15
Follow-up
Participants are monitored for any delayed symptoms or reactions after the intervention phases
Treatment Details
Interventions
- Milk containing A1 and A2 beta-casein
- Milk containing only A2 beta-casein
Milk containing A1 and A2 beta-casein is already approved in European Union, United States, Canada for the following indications:
- General nutrition
- Dietary supplement
- General nutrition
- Dietary supplement
- General nutrition
- Dietary supplement
Find a Clinic Near You
Who Is Running the Clinical Trial?
Purdue University
Lead Sponsor